The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but placing funds in companies strongly reliant on off-patent versions presents a challenging picture. Although early profits were substantial, the expiration of patents and the rise of discounted alternatives have weakened market share. Consequently, a tho